Sert Bilal M, Kristensen Gunnar B, Kleppe Andreas, Dørum Anne
Department of Gynecologic Oncology, Oslo University Hospital, Oslo, Norway.
Department of Gynecologic Oncology, Oslo University Hospital, Oslo, Norway; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
Gynecol Oncol. 2021 Aug;162(2):284-291. doi: 10.1016/j.ygyno.2021.05.028. Epub 2021 Jun 1.
To compare long-term oncological outcomes in early-stage cervical cancer (CC) patients treated with minimally invasive radical hysterectomy (MIRH) versus abdominal radical hysterectomy (ARH), with a focus on recurrence patterns, tumor sizes, and conization.
This single-institution, retrospective study consisted of stage IA1-IB1 (FIGO 2009) squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the cervix, who underwent radical hysterectomy between 2000 and 2017.
Of the 582 patients included, 353 (60.7%) underwent ARH, and 229 (39.3%) MIRH. The median follow-up was 14.4 years in the ARH group and 6.1 years in the MIRH group (p < 0.0001). Among the 96 stage IA patients, only 3 (3.1%) experienced recurrence. Among stage IB1 patients, the risk of recurrence, after adjusting for standard prognostic variables, was twofold higher in the MIRH group versus the ARH group (HR 2.73, 95% CI: 1.56-4.80), and the relative difference was similar in terms of risk of cancer-specific survival (CSS) (HR 3.04, 95% CI: 1.28-7.20) and overall survival (OS) (HR 2.35, 95% CI: 1.21-4.59). In stage IB1 ≤ 2 cm patients without conization MIRH was associated with reduced time to recurrence (TTR) (HR 4.00, 95% CI: 1.67-9.57), CSS (HR 3.71, 95% CI: 1.19-11.58) and OS (HR 3.02, 95% CI: 1.24-7.34). Intraperitoneal combined recurrences accounted for 12 of 30 (40.0%) recurrences in the MIRH group but were not identified after ARH (p = 0.0001).
MIRH was associated with reduced TTR, CSS and OS versus ARH in stage IB1 CC patients. The risk of peritoneal recurrence was high, even for tumors ≤2 cm without conization.
比较早期宫颈癌(CC)患者接受微创根治性子宫切除术(MIRH)与腹式根治性子宫切除术(ARH)后的长期肿瘤学结局,重点关注复发模式、肿瘤大小和锥切术。
这项单机构回顾性研究纳入了2000年至2017年间接受根治性子宫切除术的IA1-IB1期(国际妇产科联盟(FIGO)2009年)宫颈鳞状细胞癌、腺癌和腺鳞癌患者。
纳入的582例患者中,353例(60.7%)接受了ARH,229例(39.3%)接受了MIRH。ARH组的中位随访时间为14.4年,MIRH组为6.1年(p<0.0001)。在96例IA期患者中,仅3例(3.1%)出现复发。在IB1期患者中,在调整标准预后变量后,MIRH组的复发风险是ARH组的两倍(风险比[HR]2.73,95%置信区间[CI]:1.56-4.80),癌症特异性生存(CSS)风险(HR 3.04,95%CI:1.28-7.20)和总生存(OS)风险(HR 2.35,95%CI:1.21-4.59)的相对差异相似。在未行锥切术的IB1期≤2 cm患者中,MIRH与复发时间(TTR)缩短(HR 4.00,95%CI:1.67-9.57)、CSS(HR 3.71,95%CI:1.19-11.58)和OS(HR 3.02,95%CI:1.24-7.34)相关。MIRH组30例复发中有12例(40.0%)为腹腔内联合复发,但ARH后未发现(p=0.0001)。
与ARH相比,MIRH在IB1期CC患者中与TTR、CSS和OS降低相关。即使对于≤2 cm且未行锥切术的肿瘤,腹膜复发风险也很高。